Plain-English translation of NCT06510556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new device called the FARAFLEX Mapping and Pulsed Field Ablation System to treat atrial fibrillation — a condition where your heart beats irregularly. The device is used during a catheter procedure (a minimally invasive surgery where thin tubes are guided through blood vessels to your heart). Researchers want to learn whether this new treatment is safe and effective for people with persistent or paroxysmal atrial fibrillation.
Atrial fibrillation affects millions of people and can increase the risk of stroke and heart problems. While older ablation treatments exist, this medication uses a newer technology called pulsed field ablation that may work faster and cause less damage to surrounding heart tissue, potentially offering patients a better option.
You likely qualify if…
You likely don't qualify if…
You will undergo a catheter ablation procedure where doctors use the FARAFLEX device to map and treat the irregular electrical activity in your heart. Most participants (200 out of 250) will receive this treatment. A smaller group (about 50) may be randomly assigned to either the FARAFLEX treatment or a standard ablation device, and will also have heart imaging scans before the procedure, right after, and at 3-month and 12-month follow-up visits. You will need to attend multiple follow-up appointments to monitor your progress and heart rhythm.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Belgium
Croatia
Czechia
Italy